Facing dwindling product pipelines and looming patent cliffs, nearly all of the world's major drugmakers have recently overhauled their research and development activities. Brendan Borrell asks what difference these efforts have made.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Borrell, B. Restructurally sound. Nat Med 17, 531–533 (2011). https://doi.org/10.1038/nm0511-531
Published:
Issue Date:
DOI: https://doi.org/10.1038/nm0511-531